MindBio Therapeutics (XCNQ:MBIO) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Dividend Payout Ratio?

MindBio Therapeutics's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for MindBio Therapeutics's Dividend Payout Ratio or its related term are showing as below:

XCNQ:MBIO's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-28), the Dividend Yield % of MindBio Therapeutics is 0.00%.

MindBio Therapeutics's Dividends per Share for the months ended in Mar. 2024 was C$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

MindBio Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for MindBio Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Dividend Payout Ratio Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Dividend Payout Ratio

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of MindBio Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, MindBio Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Dividend Payout Ratio falls into.

MindBio Therapeutics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

MindBio Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2023 )	/	EPS without NRI (A: Jun. 2023 )
	=	0	/	-0.032
	=	N/A

MindBio Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	0.001
	=	0.00

MindBio Therapeutics (XCNQ:MBIO) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

MindBio Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.